REG - Adv Medical Solutns. - AMS announces US approval for LiquiBand® XL

Advanced Medical SolutionsAnnouncement

25/05/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220525:nRSY6669Ma&default-theme=true

RNS Number : 6669M  Advanced Medical Solutions Grp PLC  25 May 2022

25 May 2022

 

Advanced Medical Solutions Group plc

("AMS" or the "Group")

 

US regulatory approval for LiquiBand(®) XL

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the
world-leading specialist in tissue-healing technologies, is pleased to
announce that it has received FDA 510(k) approval for LiquiBand(®) XL, a new
device that can close longer wounds than existing LiquiBand(®) products. The
device consists of a surgical mesh which is used to close the wound and
LiquiBand(®) glue which is used to strengthen the closure and prevent
infection. Product launch into the US is expected in the third quarter of
2022.

 

The device has been used successfully on a variety of orthopaedic procedures
in multiple territories since its European approval in 2021 and has received
very positive feedback in terms ease of use, efficacy and reduced pain and
scarring in comparison with other closure methods such as stapling.

 

The addition of LiquiBand(®) XL to AMS' Advanced Wound Closure portfolio is
an important step in the development of this franchise. It provides access to
a new $60m, long wound sealant market in the US but also increases the overall
strength of the LiquiBand(®) portfolio, as it completes the range of
applications available, significantly improving the company's ability to win
new contracts and bundle products.

 

Chris Meredith, Chief Executive Officer of AMS, commented: "I am delighted to
announce the FDA approval of LiquiBand(®) XL in the US and the addition of
this product to our highly successful US LiquiBand(®) franchise. There is
strong demand for the product from hospitals and our distribution partners and
we are confident that it will make a significant impact in the market and will
play a critical role in strengthening the market share of the entire
LiquiBand(®) franchise."

 

 

- End -

 

 

For further information, please contact:

 

 Advanced Medical Solutions Group plc               Tel: +44 (0) 1606 545508
 Chris Meredith, Chief Executive Officer

 Eddie Johnson, Chief Financial Officer

 Michael King, Investor Relations

 Consilium Strategic Communications                 Tel: +44 (0) 20 3709 5700
 Mary-Jane Elliott / Matthew Neal/ Matthew Cole

 Investec Bank PLC (NOMAD & Broker)                 Tel: +44 (0) 20 7597 5970
 Daniel Adams / Gary Clarence

 HSBC Bank PLC (Broker)                             Tel: +44 (0) 20 7991 8888
 Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

 

AMS is a world-leading independent developer and manufacturer of innovative
tissue-healing technology, focused on quality outcomes for patients and value
for payers. AMS has a wide range of surgical products including tissue
adhesives, sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand(®), RESORBA(®),
LiquiBandFix8(®) and Seal-G(®). AMS also supplies wound care dressings such
as silver alginates, alginates and foams through its ActivHeal(®) brand as
well as under white label. Since 2019, the Group has made four acquisitions:
Sealantis, an Israeli medical device company with a patent-protected sealant
technology platform; Biomatlante, an established French developer and
manufacturer of innovative surgical biomaterial technologies, Raleigh, a UK
leading coater and converter of materials predominately for woundcare and
bio-diagnostics products and AFS Medical, a specialist distributor of
minimally invasive surgical devices based in Austria.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the
Czech Republic and Israel, are sold globally via a network of multinational or
regional partners and distributors, as well as via AMS's own direct sales
forces in the UK, Germany, the Czech Republic and Russia. The Group has
R&D innovation hubs in the UK, Germany, France and Israel. Established in
1991, the Group has more than 700 employees. For more information, please
see www.admedsol.com (http://www.admedsol.com/) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  REASEAFMLEESEFI